Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs1555283031
rs1555283031
A 0.700 CausalMutation CLINVAR

dbSNP: rs397507990
rs397507990
GA 0.700 GeneticVariation CLINVAR

dbSNP: rs41293497
rs41293497
G 0.700 CausalMutation CLINVAR

dbSNP: rs80359011
rs80359011
C 0.700 GeneticVariation CLINVAR

dbSNP: rs80359306
rs80359306
GA 0.700 GeneticVariation CLINVAR

dbSNP: rs80359598
rs80359598
G 0.700 CausalMutation CLINVAR

dbSNP: rs80359770
rs80359770
CA 0.700 CausalMutation CLINVAR

dbSNP: rs11571707
rs11571707
0.010 GeneticVariation BEFREE A BRCA2 germline mutation (p.Ile2490Thr), previously reported in breast cancer and, as compound heterozygote, in Fanconi anemia, was identified in the 21-year-old patient diagnosed after pregnancy, negative for cancer family history.The tumor was not available for study. 19851859

2010

dbSNP: rs80358829
rs80358829
0.020 GeneticVariation BEFREE A common variant allele (C5972T) observed in the BRCA2 gene in the Polish population is associated with an increased risk of breast cancer. 25533971

2015

dbSNP: rs11571833
rs11571833
0.740 GeneticVariation BEFREE A rare truncating BRCA2 genetic variant, rs11571833 (K3326X), has been associated with a 2.5-fold risk of lung squamous cell carcinoma but only a modest 26% increase in breast cancer risk. 25838448

2015

dbSNP: rs11571833
rs11571833
T 0.740 GeneticVariation GWASCAT Association analysis identifies 65 new breast cancer risk loci. 29059683

2017

dbSNP: rs876659602
rs876659602
0.020 GeneticVariation BEFREE Available data suggests that PALB2 c.3113G>A is a rare mutation with estimated breast cancer risks similar in magnitude to that associated with BRCA2 mutations. 23471749

2013

dbSNP: rs397507758
rs397507758
0.010 GeneticVariation BEFREE Based on the genotyping of 2 loss-of-function (LoF) variants c.5101C>T (p.GIn1701Ter [rs147021911]) and c.5791C>T (p.Arg1931Ter [rs144567652]), the FANCM gene has been suggested as a novel BC predisposition gene, while the analysis of the entire coding region of the FANCM gene in familial index cases and geographically matched controls is pending. 28033443

2017

dbSNP: rs80358807
rs80358807
0.010 GeneticVariation BEFREE Based on the genotyping of 2 loss-of-function (LoF) variants c.5101C>T (p.GIn1701Ter [rs147021911]) and c.5791C>T (p.Arg1931Ter [rs144567652]), the FANCM gene has been suggested as a novel BC predisposition gene, while the analysis of the entire coding region of the FANCM gene in familial index cases and geographically matched controls is pending. 28033443

2017

dbSNP: rs1799944
rs1799944
0.010 GeneticVariation BEFREE Carriers of the BRCA2 rs1799944 variant (991 Asp) were found to have an increased risk of breast cancer (OR = 1.41, 95% CI 1.08-1.83, P = 0.01) with P (trend) = 0.0076. 18553220

2009

dbSNP: rs144848
rs144848
0.100 GeneticVariation BEFREE Considering the relevant role of BRCA2 in MBC, we investigated whether the BRCA2 N372H variant, representing the only common non-synonymous polymorphism in BRCA2, might modulate the risk of BC in male populations. 17767707

2007

dbSNP: rs11571833
rs11571833
T 0.740 GeneticVariation GWASCAT Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations. 27197191

2016

dbSNP: rs11571818
rs11571818
C 0.700 GeneticVariation GWASCAT Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations. 27197191

2016

dbSNP: rs11571833
rs11571833
0.740 GeneticVariation BEFREE Despite classification of the BRCA2c.9976A>T, p.(Lys3326Ter) variant as a polymorphism, it has been associated with increased risks of pancreatic, lung, oesophageal and breast cancer. 26041759

2015

dbSNP: rs80358561
rs80358561
0.010 GeneticVariation BEFREE DNA sequencing from III: 22 (diagnosed with lobular BC) identified a BRCA2 exon 3 542G>T (L105X) mutation. 14735197

2004

dbSNP: rs11571833
rs11571833
0.740 GeneticVariation BEFREE For BRCA1 mutation carriers, there was a statistically significant inverse association of the K3326X variant with risk of ovarian cancer (HR = 0.43, 95% CI = 0.22 to 0.84, P = .013) but no association with breast cancer. 26586665

2016

dbSNP: rs876659602
rs876659602
0.020 GeneticVariation BEFREE For European women, strong evidence of association with breast cancer risk was observed for PALB2 c.1592delT OR 3.44 (95% CI 1.39 to 8.52, p=7.1×10<sup>-5</sup>), PALB2 c.3113G>A OR 4.21 (95% CI 1.84 to 9.60, p=6.9×10<sup>-8</sup>) and ATM c.7271T>G OR 11.0 (95% CI 1.42 to 85.7, p=0.0012). 27595995

2016

dbSNP: rs80358527
rs80358527
0.020 GeneticVariation BEFREE For five SNPs--CASP8 D302H, IGFBP3 -202 c>a, PGR V660L, SOD2 V16A, and TGFB1 L10P--the associations with breast cancer were of borderline statistical significance (P = .016, .060, .047, .056, and .0088 respectively). 17018785

2006

dbSNP: rs1057520611
rs1057520611
0.010 GeneticVariation BEFREE Four previously reported polymorphisms (K1183R, S1613G, and M1652I in BRCA1, and 7470A>G in BRCA2) were detected in both controls and breast cancer patients. 17018160

2006

dbSNP: rs4942440
rs4942440
0.010 GeneticVariation BEFREE Furthermore, there was suggestive evidence that the minor allele of SNP rs4942440, which is associated with higher BRCA2 expression, is also associated with a reduced risk of breast cancer (per-allele hazard ratio (HR) = 0.85, 95% confidence interval (CI) = 0.72 to 1.00, P-trend = 0.048). 22513257

2012